<DOC>
	<DOCNO>NCT01209858</DOCNO>
	<brief_summary>The purpose study investigate effect perampanel pharmacokinetics ( PK ) single-dose oral contraceptive ( OC ) contain ethinylestradiol ( EE ) levonorgestrel ( LN ) ( Microgynon-30 ) investigate effect repeat dose OC contain EE LN ( Microgynon-30 ) PK single dose perampanel .</brief_summary>
	<brief_title>A Study Investigate Potential Pharmacokinetic Interaction Perampanel With Oral Contraceptives Healthy Female Subjects</brief_title>
	<detailed_description>This open-label , non-randomized , fix sequence study healthy female subject . The study 2 part : Part A investigating effect steady state perampanel pharmacokinetics ( PK ) single-dose oral contraceptive ( OC ) contain ethinylestradiol ( EE ) levonorgestrel ( LN ) ( Microgynon-30 ) Part B investigate effect repeat dose OC contain EE LN ( Microgynon-30 ) PK single dose perampanel .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>1 . Healthy female subject , age 18 55 year old inclusive Screening ; 2 . Body mass index ( BMI ) within range 1832 kg/m^2 inclusive Screening ; 3 . Must take form hormonal contraceptive , include hormonal intrauterine device ( IUD ) , least 8 week prior dose ; 4 . All female must negative serum beta human chorionic gonadotropin ( B hCG ) test result Screening negative urine BhCG test result Baseline . Females childbearing potential must agree use 2 medically acceptable method contraception ( eg , abstinence subject 's preferred lifestyle , nonhormonal intrauterine device , doublebarrier method condom + spermicide condom + diaphragm spermicide , vasectomized partner confirm azoospermia ) throughout entire study period 4 week study drug discontinuation . The subject exempt requirement postmenopausal woman ( define least 12 month consecutive amenorrhea , appropriate age group , without know suspected primary cause ) subject sterilize surgically otherwise prove sterile ( ie , bilateral tubal ligation surgery least 1 month prior dose , hysterectomy , bilateral oophorectomy surgery least 1 month prior dose ) ; 5 . With known contraindication Microgynon30 ; 6 . Are willing able comply aspect protocol ; 7 . Provide write informed consent . 1 . Have evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematological , neurological , psychiatric disease abnormality know history gastrointestinal surgery ( include cholecystectomy ) could impact PK study drug ; 2 . Have know history clinically significant drug food allergy presently experience seasonal allergy ; 3 . Have inability tolerate venipuncture and/or venous access ; 4 . Have history alcohol abuse ( within past 6 month ) drink maximum recommended number unit alcohol per week ( 14 unit woman ) unwilling abstain consumption alcohol throughout period inpatient confinement ; 5 . Have history drug abuse dependence positive result urine drug screen test ; 6 . Received experimental drug within 12 week lead start study drug treatment currently enrol another clinical trial ; 7 . Smoke 5 cigarette ( equivalent amount tobacco ) per day unwilling abstain use nicotinecontaining product throughout period inpatient confinement ; 8 . Consume 5 caffeinated beverage per day ( eg , 5 cup tea , coffee can cola ) unwilling abstain consumption caffeinecontaining food beverage throughout period inpatient confinement ; 9 . Have take inhibitor CYP450 within 2 week prior first dose ( eg , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple Seville orange product ) ; 10 . Donated blood blood product within 12 week prior start dose intent donate blood study within 8 week completion study ; 11 . With QTcF interval great 450 msec Screening either Baseline family history prolong QTc syndrome sudden death ; 12 . With positive result Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCVAb ) screen Screening ; 13 . Have diagnose acquire immune deficiency syndrome ( AIDS ) , test positive human immunodeficiency virus ( HIV ) Screening ; 14 . With positive alcohol test Screening either Baseline ; 15 . With Screening hemoglobin low limit normal [ LLN ] and/or hematological parameter consistent acute chronic blood loss ( hematocrit [ Hct ] LLN , mean corpuscular hemoglobin [ MCH ] LLN mean corpuscular hemoglobin concentration [ MCHC ] LLN ) ; 16 . Taking , take , prescribed overthecounter drug herbal remedy 2 week prior Screening ( unless OTC drug long halflife [ ie , 5 x t1/2 great 2 week ] ) exception paracetamol , allow 12 hour prior dose ; 17 . Within 4 week prior dose , special diet take dietary aid know induce CYP3A4 ( eg , St John 's Wort ) ; 18 . Have know personal family history arterial/venous thrombosis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>epilepsy</keyword>
</DOC>